CLEVELAND, June 4, 2014 /PRNewswire/ -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, has developed a commercial version of Indego®, a powered lower limb orthotic device also referred to as an exoskeleton. This version of Indego would enable clinicians to conduct over ground, task specific gait training and potentially allow people with mobility impairments, such as spinal cord injury, a new level of independence. The company recently demonstrated the device at the OT World trade show in Germany and has launched a new website at www.indego.com. Indego has not yet been submitted for United States FDA approval and is not available for sale.
"Indego is just one example of an entirely new category of wearable robotic devices that simulate natural human motion and hold the potential to offer new methods of therapy and greater independence for those with mobility impairments." said Achilleas Dorotheou, head of the human motion and control business unit for Parker. "Our engineering team has sought to significantly improve on the distinguishing features of Indego with this new version. We are excited to be progressing towards making this device available commercially in Europe in 2015 and in the United States in 2016."
Designed for personal use and as a therapy tool, Indego has numerous features that could potentially assist mobility impaired patients:
- Modular Design - Indego has a modular design, self-aligning connections, and single hand adjustment strapping system.
- Lightweight - At just 26 lbs, Indego is light, and allows for quick set-up and transport.
- Control - Indego uses postural position to operate and includes vibratory feedback, LED indicators and a wireless software interface.
- Indego's software app offers control over parameters such as stride length, step frequency and can archive data for each patient.
Parker is working to secure the regulatory approvals and CE marking for Indego in Europe, which are expected by the end of 2014, and is currently establishing partnerships with leading institutions in the region. Parker also aims at having Indego become the first powered lower limb orthotic device to receive FDA approval in the United States.
To learn more about Indego, visit www.indego.com.
About Parker Hannifin With annual sales of $13 billion in fiscal year 2013, Parker Hannifin is the world's leading diversified manufacturer of motion and control technologies and systems, providing precision-engineered solutions for a wide variety of mobile, industrial and aerospace markets. The company employs approximately 58,000 people in 49 countries around the world. Parker has increased its annual dividends paid to shareholders for 58 consecutive fiscal years, among the top five longest-running dividend-increase records in the S&P 500 index. For more information, visit the company's web site at www.parker.com, or its investor information web site at www.phstock.com.
SOURCE Parker Hannifin Corporation